Paroxetine Treatment of Generalized Social Phobia (Social Anxiety Disorder): A Randomized Controlled Trial
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
CONTEXT: The generalized type of social phobia (social anxiety disorder) is a severe and often disabling form of social anxiety that affects approximately 5% of the general population. Earlier research has shown monoamine oxidase inhibitors or benzodiazepines to be effective in treating this condition, but neither has achieved widespread use. OBJECTIVE: To compare the efficacy of paroxetine, a selective serotonin reuptake inhibitor, with placebo in adults with generalized social phobia. DESIGN: Twelve-week, multicenter, randomized, double-blind trial. SETTING: Thirteen centers across the United States and 1 in Canada. PARTICIPANTS: Between April 13, 1995, and February 28, 1996, 187 persons meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for generalized social phobia were randomized (and 183 returned for at least 1 efficacy assessment) to treatment. INTERVENTION: After a 1-week, single-blind, placebo, run-in period, patients received a double-blind, 11-week course of either paroxetine or matching-image placebo. The initial daily dosage of paroxetine (or placebo) was 20 mg with increases of 10 mg/d weekly (flexible dosing to a maximum of 50 mg/d) permitted after the second week of treatment. MAIN OUTCOME MEASURES: Number of responders based on the Clinical Global Impression Global Improvement Item ("much improved" or "very much improved"); mean change from baseline on the Liebowitz Social Anxiety Scale total score. RESULTS: Fifty (55.0%) of 91 persons taking paroxetine and 22 (23.9%) of 92 persons taking placebo were much improved or very much improved at the end of treatment (odds ratio [OR], 3.88; 95% confidence interval [CI], 2.81-5.36). Mean Liebowitz Social Anxiety Scale total scores were reduced by 39.1% (the mean baseline score of 78.0 declined by a mean of 30.5 points at follow-up) in the paroxetine group compared with 17.4% (the mean baseline score of 83.5 declined 14.5 points at follow-up) in the placebo group, a difference of 21.7% (95% CI, 8.7%-34.7%) favoring paroxetine. CONCLUSIONS: Paroxetine is an effective treatment for patients with generalized social phobia. Short-term (ie, 11-week) treatment results in substantial and clinically meaningful reductions in symptoms and disability. Future research should test whether these may be further reduced by extended treatment or supplementation with specific educational-cognitive-behavioral techniques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Measurement of social-evaluative anxiety.
Watson, D., & Friend, R. (1969) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0027806 · Cited by 3,467
Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.272.22.1749 · Cited by 2,635
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
Magee, W. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020077009 · Cited by 996
Spitzer, R. L. (1995) · JAMA · doi:10.1001/jama.274.19.1511 · Cited by 684
Social Phobia: Review of a Neglected Anxiety Disorder
Liebowitz, M. R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790300097013 · Cited by 577
Self-citationFunctional impairment in social phobia.
Schneier, F. R., Heckelman, L., Garfinkel, R. S., Campeas, R. B., Fallon, B. A., Gitow, A., Street, L. L., Bene, D. D., & Liebowitz, M. R. (1994) · PubMed · Cited by 534
Self-citationPhenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
Self-citation
Cited by
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
FRESCO, D. M., COLES, M. E., HEIMBERG, R. G., LIEBOWITZ, M. R., HAMI, S., STEIN, M. B., & GOETZ, D. (2001) · Psychological Medicine · doi:10.1017/s0033291701004056 · Cited by 874
“The LSAS has been used in most clinical trials of medications for social anxiety disorder (Lott et al. 1997; Noyes et al. 1997; Stein et al. 1998) and it is being used with increasing frequency in studies evaluating the efficacy of cognitive–behavioural treatments as well (e.”
MethodSelf-citationBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
The Liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis
Baker, S. L., Heinrichs, N., Kim, H.-J., & Hofmann, S. G. (2002) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(01)00060-2 · Cited by 640
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Self-citationClark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560
Mennin, D. S., Fresco, D. M., Heimberg, R. G., Schneier, F. R., Davies, S. O., & Liebowitz, M. R. (2002) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(02)00134-2 · Cited by 506
Self-citationSheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1982 · Cited by 432
Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415
Psychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396
Barriers to the Treatment of Social Anxiety
Olfson, M., Guardino, M., Struening, E., Schneier, F. R., Hellman, F., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.521 · Cited by 356
Paroxetine: An Update of Its Use in Psychiatric Disorders in Adults
Wagstaff, A. J., Cheer, S. M., Matheson, A. J., Ormrod, D., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262040-00010 · Cited by 287
Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder
ZAIDER, T. I., HEIMBERG, R. G., FRESCO, D. M., SCHNEIER, F. R., & LIEBOWITZ, M. R. (2003) · Psychological Medicine · doi:10.1017/s0033291703007414 · Cited by 286
Self-citationImpact of Generalized Social Anxiety Disorder in Managed Care
Katzelnick, D. J., Kobak, K. A., DeLeire, T., Henk, H. J., Greist, J. H., Davidson, J. R. T., Schneier, F. R., Stein, M. B., & Helstad, C. P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1999 · Cited by 262
Self-citationStein, M. B., Fyer, A. J., Davidson, J. R. T., Pollack, M. H., & Wiita, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.756 · Cited by 262
Self-citationFeltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., & Pande, A. C. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 260
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240
“6%) was higher than that reported for adults treated with paroxetine for social anxiety disorder (55%).(11) The mean dose of paroxetine treatment in this study was 24.”
ResultSelf-citationPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Self-citationComer, J. S., Blanco, C., Hasin, D. S., Liu, S.-M., Grant, B. F., Turner, J. B., & Olfson, M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05094blu · Cited by 214
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
BackgroundRandall, C. L., Thomas, S., & Thevos, A. K. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02201.x · Cited by 188
Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(00)00027-x · Cited by 175
Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment
Brunello, N., den Boer, J. A., Judd, L. L., Kasper, S., Kelsey, J. E., Lader, M., Lecrubier, Y., Lepine, J. P., Lydiard, R. B., Mendlewicz, J., et al. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00140-8 · Cited by 153
Self-citationExposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial
Haug, T. T., Blomhoff, S., Hellstrøm, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.312 · Cited by 151
Optogenetic insights on the relationship between anxiety-related behaviors and social deficits
Allsop, S. A., Vander Weele, C. M., Wichmann, R., & Tye, K. M. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00241 · Cited by 150
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Selective mutism and social anxiety disorder: All in the family?
CHAVIRA, D. A., SHIPON-BLUM, E., HITCHCOCK, C., COHAN, S., & STEIN, M. B. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318149366a · Cited by 127
“Data support differences in severity, comorbidity, and etiologies across the subtypes (Chavira et al., 2004; Wittchen et al., 1998), with some data suggesting that the generalized type may have a more temperamental and perhaps heritable basis (Stein et al., 1998a,b; Stemberger et al., 1995).”
BackgroundSelf-citationHofmann, S. G., Smits, J. A. J., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., & Pollack, M. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070974 · Cited by 121
Weeks, J. W., Spokas, M. E., & Heimberg, R. G. (2007) · Depression and Anxiety · doi:10.1002/da.20250 · Cited by 106
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Self-citationWong, J., Gordon, E. A., & Heimberg, R. G. (2012) · Handbook of Evidence-Based Practice in Clinical Psychology · doi:10.1002/9781118156391.ebcp002027 · Cited by 96
Social Phobia: Epidemiology and Cost of Illness
Lipsitz, J. D., & Schneier, F. R. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018010-00003 · Cited by 92
Pharmacotherapy of social anxiety disorder
Blanco, C., Antia, S. X., & Liebowitz, M. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01294-x · Cited by 88
Self-citationPharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84
Anxiety and Depression: Optimizing Treatments
Ballenger, J. C. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0301 · Cited by 83
Evidence-based pharmacotherapy for personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000071 · Cited by 83
Childhood Social Anxiety Disorder: From Understanding to Treatment
Chavira, D. A., & Stein, M. B. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.05.003 · Cited by 71
Self-citationPharmacotherapy of social phobia
Davidson, J. R. T. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.7.x · Cited by 69
Social anxiety disorder/social phobia: Epidemiology, diagnosis, neurobiology, and treatment
den Boer, J. A. (2000) · Comprehensive Psychiatry · doi:10.1053/comp.2000.16564 · Cited by 67
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Watanabe, N., Furukawa, T. A., Chen, J., Kinoshita, Y., Nakano, Y., Ogawa, S., Funayama, T., Ietsugu, T., & Noda, Y. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-81 · Cited by 50
“In comparison with patients treated with placebo pills, several RCTs reported improvements in some QoL measures after treatment with a variety of antidepressants [15-17].”
ResultMeta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Curtiss, J., Andrews, L., Davis, M., Smits, J., & Hofmann, S. G. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285907 · Cited by 46
“ment in more general mental health domains such as QOL [10,11].”
BackgroundNagata, T., Suzuki, F., & Teo, A. R. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12327 · Cited by 40
Liebowitz, M. R., Salman, E., Nicolini, H., Rosenthal, N., Hanover, R., & Monti, L. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.12101342 · Cited by 36
MONTGOMERY, S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.06.001 · Cited by 18
Hofmann, S. G., Gutner, C. A., & Fang, A. (2012) · Encyclopedia of Human Behavior · doi:10.1016/b978-0-12-375000-6.00330-x · Cited by 2
Psychopharmacology for Social Anxiety Disorder
Blanco, C., Bragdon, L., Schneier, F. R., & Liebowitz, M. R. (2014) · Social Anxiety · doi:10.1016/b978-0-12-394427-6.00022-4 · Cited by 2
Self-citationHofmann, S. G., Gutner, C. A., & Fang, A. (2017) · Reference Module in Neuroscience and Biobehavioral Psychology · doi:10.1016/b978-0-12-809324-5.06570-6 · Cited by 1
Efficacy of Paroxetine for Relapse Prevention in Social Anxiety Disorder: A 24-Week Study
Stein, D. J., Versiani, M., Hair, T., & Kumar, R. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1111
Metadata
- Authors
- Stein, M. B., Liebowitz, M. R., Lydiard, R. B., Pitts, C. D., Bushnell, W., & Gergel, I.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1998-08-26
- Volume
- 280
- Issue
- 8
- Pages
- 708
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1994095895
- Cited by
- 348
- References
- 42
- FWCI
- 56.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.